Pfizer ends its COVID-19 vaccine trial with a 95% success rate

Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.
Read more: https://uk.reuters.com/article/uk-health-coronavirus-vaccines-pfizer/pfizer-ends-covid-19-trial-with-95-efficacy-to-seek-emergency-use-authorization-idUKKBN27Y1HK?source=Snapzu